Vertex Pharmaceuticals (VRTX) Net Income (2009 - 2026)

Vertex Pharmaceuticals has reported Net Income for 18 years, with the latest figure at $1.1 billion in Q2 2026.

• On a quarterly basis, Net Income rose 6.48% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $4.4 billion, a 21.1% increase from a year earlier, with the FY2025 full-year figure at $4.0 billion, up 838.09% from the prior year.
• Net Income was $1.1 billion for Q2 2026 at Vertex Pharmaceuticals, up from $1.0 billion in the prior quarter.
• The five-year high for Net Income was $1.2 billion in Q4 2025, with the low at -$3.6 billion in Q2 2024.
• Average Net Income over 5 years is $693.9 million, with a median of $949.6 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Net Income soared 1109.7% in 2022, then slumped 492.44% in 2024.
• Over 5 years, Net Income stood at $818.9 million in 2022, then rose by 18.31% to $968.8 million in 2023, then slipped by 5.76% to $913.0 million in 2024, then surged by 30.46% to $1.2 billion in 2025, then dropped by 7.67% to $1.1 billion in 2026.
• The last three Net Income figures came in at $1.1 billion (Q2 2026), $1.0 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.